arrow
Y

Yashaswi Shrestha

Novartis
H指数:24
被引数:2,894

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Circulating tumor DNA (ctDNA) clearance with neoadjuvant durvalumab (D) plus tremelimumab (T) plus enfortumab vedotin (EV) for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) from the safety run-in cohort of the phase III VOLGA trial

VOLGA III期试验安全启动队列中,使用新辅助度伐利尤单抗(D)联合特瑞普利单抗(T)和恩沃利单抗(EV)治疗不适合顺铂的肌肉浸润性膀胱癌(MIBC)患者的循环肿瘤DNA(ctDNA)清除情况。

2024-09-011
PRE
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study
2024-05-304
OAAI
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2021-07-0651
OA
Durvalumab(D) ± tremelimumab(T) plus platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN
2021-07-010
PREAI
Behavioural and neurochemical mechanisms underpinning the feeding-suppressive effect of GLP-1/CCK combinatorial therapy

行为和神经化学机制支持GLP-1/CCK联合疗法的摄食抑制作用

2021-01-018
OAAI
c-Kit-positive ILC2s exhibit an ILC3-like signature that may contribute to IL-17-mediated pathologies (vol 20, pg 992, 2019)

C-kit阳性ilc2表现出可能导致IL-17-mediated病理的ILC3-like特征 (第20卷,992页,2019页)

2019-11-131
OAAI
c-Kit-positive ILC2s exhibit an ILC3-like signature that may contribute to IL-17-mediated pathologies

C-kit阳性ilc2表现出可能导致IL-17-mediated病理的ILC3-like特征

2019-07-01141
PREAI